Targeting the IL-1β pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-22-0290
Abstract: High levels of IL-1β can result in chronic inflammation, which in turn can promote tumor growth and metastasis. Inhibition of IL-1β could therefore be a promising therapeutic option in the treatment of cancer. Here, the… read more here.
Keywords: targeting pathway; pathway cancer; canakinumab gevokizumab; tumor microenvironment ... See more keywords